Singulex is a commercial stage company pioneering Next Generation Immunodiagnostics (NGI). Singulex's proprietary Single Molecule Counting technology is the backbone of NGI, and provides unprecedented ultra-sensitivity in the precision measurement of biomarkers.
Location: United States, California, Alameda
Employees: 51-200
Total raised: $84.5M
Founded date: 1997
Investors 3
Funding Rounds 3
Date | Series | Amount | Investors |
26.09.2013 | - | $55M | - |
14.01.2009 | - | $19M | - |
20.09.2006 | - | $10.5M | - |
Mentions in press and media 5
Date | Title | Description | Source |
26.09.2013 | Singulex Closes $55M Financing | Singulex, Inc., a Alameda, CA-based provider of Single Molecule Counting (SMC™) technology for scien... | finsmes.co... |
14.01.2009 | Singulex lands $19M for diagnostic systems | Singulex, an Alameda, Calif.-based biotech firm, just raised $19 million in fifth-round funding to c... | venturebea... |
08.06.2007 | Biomarker diagnostics company Singulex raises $19M | See our story here at VentureBeat LifeSciences. VentureBeat VentureBeat's mission is to be a digita... | venturebea... |
07.06.2007 | Biomarker-diagnostics developer Singulex validates $19M | Hayward, Calif.-based Singulex, a developer of sensitive molecular-detection systems, raised $19 mil... | venturebea... |
20.09.2006 | Molecular detection Co., Singulex, raises $10.5M | Singulex, a Hayward company developing “bio-markers” to detect the presence in the body of certain p... | venturebea... |